Streetbeat News

Stock Prices

LOVE

Lovesac has revised its fiscal 2025 outlook, lowering its net sales forecast to $700M-$735M from the previous $700M-$770M, compared to a $732.2M estimate. The diluted EPS is now expected to be $1.01-$1.26, down from $1.06-$1.59, against a $1.23 estimate.

Portfolio Pulse from Benzinga Newsdesk

September 12, 2024 | 11:08 am

LOVE

Lovesac has revised its Q3 net sales forecast to $152M-$160M, below the $165.70M estimate. The company also expects a basic loss per share of $(0.28)-$(0.50), compared to the previous estimate of a $0.10 profit.

Portfolio Pulse from Benzinga Newsdesk

September 12, 2024 | 11:05 am

LOVE

Lovesac reported a Q2 2025 GAAP EPS of $(0.38), beating the estimate of $(0.44), but sales of $156.590M missed the $156.996M estimate. Sales increased by 1.33% compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

September 12, 2024 | 11:02 am

CAL

Caleres shares declined following the release of disappointing Q2 financial results and a reduction in the company's annual outlook.

Portfolio Pulse from Benzinga Newsdesk

September 12, 2024 | 10:58 am

FULC

Fulcrum Therapeutics has announced the suspension of future development of its drug Losmapimod. This decision may impact the company's stock as investors react to the halt in development.

Portfolio Pulse from Benzinga Newsdesk

September 12, 2024 | 10:57 am

FULC

Fulcrum Therapeutics announced that its Phase 3 REACH trial for Losmapimod in treating facioscapulohumeral muscular dystrophy did not meet its primary or secondary endpoints. This could negatively impact the company's stock in the short term.

Portfolio Pulse from Benzinga Newsdesk

September 12, 2024 | 10:57 am

VFS

The National Highway Traffic Safety Administration (NHTSA) has initiated a preliminary evaluation into VinFast Auto Ltd.'s VF8 vehicles due to complaints about the Lane Keep Assist system. The system reportedly activates in error, struggles to detect lanes, and provides improper steering inputs, potentially increasing crash risks. The investigation will determine if a safety issue exists in the 2023-2024 VF8 models.

Portfolio Pulse from Anan Ashraf

September 12, 2024 | 10:55 am

CAL

Caleres has announced its expectations for Q3 sales to be flat to down 2%, with adjusted EPS projected between $1.30 and $1.40, below the estimated $1.50.

Portfolio Pulse from Benzinga Newsdesk

September 12, 2024 | 10:52 am

CAL

Caleres has revised its FY24 EPS outlook downward from $4.30-$4.60 to $3.94-$4.09, with adjusted EPS guidance set at $4.00-$4.15, below the estimated $4.42. The adjusted EPS excludes $3 million in restructuring costs expected in Q3.

Portfolio Pulse from Benzinga Newsdesk

September 12, 2024 | 10:50 am

CAL

Caleres has revised its fiscal year 2024 net sales outlook to a decrease in the low-single-digits percentage, compared to its previous guidance of flat to a 2% increase.

Portfolio Pulse from Benzinga Newsdesk

September 12, 2024 | 10:48 am